Dubai,Bangkok, Singapore, Hong Kong, London, New York & San Francisco

US based Biotech / Pharma / BioPharma SPV plans merger with a listed SPAC @ Nasdaq

The SPV being incorporated as an Operating company in the domain of  in Biotech / Pharma / BioPharma with business interests in Drug Research / Discovery using AI- Accelerated Solutions / Methodologies for Accelerated Drug Development / Delivery

Currently Inviting companies which are active in the domains of Biotech / Pharma / BioPharma, Developing Life Saving Drugs / Medicines using AI-Accelerated Development tools, to partner with our SPV for quick Launch across global markets, Get big ticket Investment thru SPAC merger and Listing at Nasdaq, USA in a SPAN of 6 months.

Tech Venture SPV - Lead Promoter

US based Tech Venture Investment Advisory with interests in Space Tech, Urban Mobility related Commercial Drones, eVTOLs, BEVs, FCVs, Climate Change, Heathcare & Pharma and Clean Tech Ventures.

Pre-IPO Investors

Biotech / Pharma Tech focused Venture Capitalists, Family Offices, Funds, Institutional Investors, Angel Funds / Syndicates and HNWIs which will invest in the US based Biotech / BioPharma SPV validating its business model

Inviting Drug Discovery companies

Seeking collaborative partnership with Biotech / Pharma / BioPharma companies engaged in Drug Development and Delivery - Both Early stage / Matured companies with Patents / Trials / FDA approvals ongoing ..

Inviting AI Solution providers

Seeking collaborative partnership with companies which are into providing AI-Accelerated Drug Development / Delivery tools specially designed early / Late stage biotech / pharma companies .

Inviting BioPharma Drug Makers / Mfrs

Seeking partnership / licensing deals with Pharmaceutical manufacturers for commercial production, approval and distribution across global markets.

Launch Plans Q1-2, 2024

The JV / Collaborative Partnership based BioPharma project is expected to be structured and incorporated in Q1, 2024 and subsequently Launch plans will be in Q2, 2024.

SPAC merger is expected to bring in approx $40M Investment to the merged entity.
$40 M
Investment availability for Drug Development, Early stage trials with AI Accelerated Methodologies
$5 M
Investment availability for Drug Development, Late Stage trials with AI-Accelerated Methodologies
$10 M
Global Expansion, Licensing deals and acquisitions
$15 M
Operating expenses post merger after SPAC advisory fees
$5 M

Proposed BioPharma / Biotech SPV Operating Co's Shareholding Structure - Post merging with a SPAC

Lead SPV Promoter – 5%
Pre-IPO Investors   – 15% ( subject to quantum of investment )
SPAC Investors – 30% ( subject to availability of funds during merger )
*BioPharma / AI Technology Operating Companies  – 50% 

Listed SPACs available @ Nasdaq for Merger with Current Funds available from $20M to $100M

SPAC Takeover / Merger / Operating *Expenses – $1.5M to $2,5M
SPAC Advisor *Expenses – $500K*

The above initial *Expenses and other operating expenses will be met from Pre-IPO investors.

Welcome to partner with us for Accelerated Growth and Investment

Global Partners



Click our representatives below to chat on WhatsApp or send us an email to

× Hi, Lets Chat